Apyx Medical (Apyx Medical) Cash-to-Debt

: 1.13 (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Apyx Medical's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.13.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Apyx Medical could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Apyx Medical's Cash-to-Debt or its related term are showing as below:

APYX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.13 Med: 8.75 Max: 559.1
Current: 1.13

During the past 13 years, Apyx Medical's highest Cash to Debt Ratio was 559.10. The lowest was 1.13. And the median was 8.75.

APYX's Cash-to-Debt is ranked worse than
59.86% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs APYX: 1.13

Apyx Medical Cash-to-Debt Historical Data

The historical data trend for Apyx Medical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Apyx Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

51.91

62.00

101.21

12.80

1.13

Apyx Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															12.80	1.71	1.28	1.54	1.13

Competitive Comparison

For the Medical Devices subindustry, Apyx Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apyx Medical Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Apyx Medical's Cash-to-Debt falls into.

Apyx Medical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Apyx Medical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	43.652	/	(0.367	+	38.134)
	=	1.13

Apyx Medical's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	43.652	/	(0.367	+	38.134)
	=	1.13

Apyx Medical (NAS:APYX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Apyx Medical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Apyx Medical (Apyx Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BOV:Germany

Address

5115 Ulmerton Road, Clearwater, FL, USA, 33760

Website

https://apyxmedical.com

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Executives

Todd Hornsby	officer: Executive Vice President	14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine	director	75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb	officer: Chief Financial Officer	5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal	director	5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty	director	1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman	director	5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres	director	86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers	officer: Chief Financial Officer	4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron	director, officer: President
Robert Gershon	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii	officer: Chief CommercializationOfficer	23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson	director	C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz	officer: Vice President of Operations